HUE055170T2 - Hepatitis-B vírus felszíni antigén inhibitor - Google Patents

Hepatitis-B vírus felszíni antigén inhibitor

Info

Publication number
HUE055170T2
HUE055170T2 HUE18763490A HUE18763490A HUE055170T2 HU E055170 T2 HUE055170 T2 HU E055170T2 HU E18763490 A HUE18763490 A HU E18763490A HU E18763490 A HUE18763490 A HU E18763490A HU E055170 T2 HUE055170 T2 HU E055170T2
Authority
HU
Hungary
Prior art keywords
hepatitis
surface antigen
virus surface
antigen inhibitor
inhibitor
Prior art date
Application number
HUE18763490A
Other languages
English (en)
Inventor
Fei Sun
Jinhua Du
Yanbin Hu
Lili Zhou
Charles Z Ding
Shuhhui Chen
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of HUE055170T2 publication Critical patent/HUE055170T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE18763490A 2017-03-09 2018-03-09 Hepatitis-B vírus felszíni antigén inhibitor HUE055170T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710138275 2017-03-09

Publications (1)

Publication Number Publication Date
HUE055170T2 true HUE055170T2 (hu) 2021-11-29

Family

ID=63447286

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18763490A HUE055170T2 (hu) 2017-03-09 2018-03-09 Hepatitis-B vírus felszíni antigén inhibitor

Country Status (25)

Country Link
US (1) US11008331B2 (hu)
EP (1) EP3590942B1 (hu)
JP (1) JP6783424B2 (hu)
KR (1) KR102087397B1 (hu)
CN (1) CN109071564B (hu)
AU (1) AU2018232071B2 (hu)
BR (1) BR112019018650B1 (hu)
CA (1) CA3055442C (hu)
DK (1) DK3590942T3 (hu)
EA (1) EA038122B9 (hu)
ES (1) ES2879930T3 (hu)
HR (1) HRP20211331T1 (hu)
HU (1) HUE055170T2 (hu)
IL (1) IL269142B (hu)
LT (1) LT3590942T (hu)
MX (1) MX2019010736A (hu)
MY (1) MY174224A (hu)
PH (1) PH12019502052A1 (hu)
PL (1) PL3590942T3 (hu)
PT (1) PT3590942T (hu)
RS (1) RS62094B1 (hu)
SG (1) SG11201908101YA (hu)
SI (1) SI3590942T1 (hu)
WO (1) WO2018161960A1 (hu)
ZA (1) ZA201906252B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
ES2938341T3 (es) 2016-03-07 2023-04-10 Enanta Pharm Inc Agentes antivirales contra la hepatitis B
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
WO2019046271A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019169539A1 (en) * 2018-03-05 2019-09-12 Pharmaresources (Shanghai) Co., Ltd. Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CA3111792A1 (en) 2018-09-05 2020-03-12 Children's Medical Center Corporation Papd5 inhibitors and methods of use thereof
MX2021003253A (es) 2018-09-21 2021-08-11 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales.
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
AU2019385477A1 (en) 2018-11-21 2021-06-10 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11807647B2 (en) 2019-09-19 2023-11-07 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of hepatitis B surface antigen inhibitor and application thereof
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN115515595A (zh) * 2020-05-15 2022-12-23 福建广生中霖生物科技有限公司 用于治疗乙肝的组合
WO2021228213A1 (zh) 2020-05-15 2021-11-18 福建广生堂药业股份有限公司 包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
EP4251621A1 (en) * 2020-11-25 2023-10-04 F. Hoffmann-La Roche AG Aromatic spiro ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN116744932A (zh) * 2021-01-15 2023-09-12 福建广生中霖生物科技有限公司 一种手性噁嗪类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251647A1 (en) * 2011-09-20 2013-09-26 Basf Se Low molecular weight modulators of the cold menthol receptor trpm8 and use thereof
CN103450184A (zh) * 2012-05-29 2013-12-18 上海壹志医药科技有限公司 斯氏紫堇碱衍生物的盐
WO2015113990A1 (en) 2014-01-30 2015-08-06 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EP3256471B1 (en) * 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
JP6598974B2 (ja) 2015-07-21 2019-10-30 エフ.ホフマン−ラ ロシュ アーゲー B型肝炎ウイルス感染症の治療および予防のための新規な三環式4−ピリドン−3−カルボン酸誘導体
WO2017017043A1 (en) 2015-07-28 2017-02-02 F. Hoffmann-La Roche Ag Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
CN107759585A (zh) * 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用

Also Published As

Publication number Publication date
KR102087397B1 (ko) 2020-03-11
ZA201906252B (en) 2021-04-28
AU2018232071A1 (en) 2019-10-17
SI3590942T1 (sl) 2021-11-30
US11008331B2 (en) 2021-05-18
HRP20211331T1 (hr) 2021-11-26
EA201992082A1 (ru) 2020-02-12
EP3590942A4 (en) 2020-01-08
SG11201908101YA (en) 2019-10-30
MX2019010736A (es) 2019-11-05
EA038122B9 (ru) 2021-09-14
DK3590942T3 (da) 2021-09-06
KR20190117799A (ko) 2019-10-16
IL269142B (en) 2020-07-30
JP2020509075A (ja) 2020-03-26
AU2018232071B2 (en) 2021-07-08
US20200039995A1 (en) 2020-02-06
PH12019502052A1 (en) 2020-07-06
BR112019018650A2 (pt) 2020-04-07
CA3055442A1 (en) 2018-09-13
RS62094B1 (sr) 2021-08-31
CN109071564B (zh) 2019-08-27
CA3055442C (en) 2021-03-23
CN109071564A (zh) 2018-12-21
LT3590942T (lt) 2021-07-12
PL3590942T3 (pl) 2021-12-13
EP3590942A1 (en) 2020-01-08
WO2018161960A1 (zh) 2018-09-13
MY174224A (en) 2020-03-23
ES2879930T3 (es) 2021-11-23
EA038122B1 (ru) 2021-07-09
JP6783424B2 (ja) 2020-11-11
EP3590942B1 (en) 2021-06-09
BR112019018650B1 (pt) 2021-12-14
PT3590942T (pt) 2021-07-28

Similar Documents

Publication Publication Date Title
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
HK1257480A1 (zh) 工程病毒
IL264575A (en) RNA materials for hepatitis b virus infection
HK1256869A1 (zh) 強力地中和乙型肝炎病毒的抗體和其用途
EP3632914A4 (en) HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR
SG11201605691VA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
SI3441389T1 (sl) Pirazol-oksazolidinonska spojina proti virusu hepatitisa B
IL267785A (en) virus
EP3360896A4 (en) ANTIBODIES TO HEPATITIS B SURFACE ANTIGEN AND USE THEREOF
EP4063383A4 (en) ANTIBODIES AGAINST VARICELLA ZOSTER VIRUS
GB201820983D0 (en) Virus
EP3473639A4 (en) HEPATITIS-C VIRUS INHIBITOR AND APPLICATION
EP3445367A4 (en) INHIBITORS OF HEPATITIS C VIRUS
GB201702193D0 (en) Hepatitis E virus vaccine
GB201813175D0 (en) Virus use
GB201707106D0 (en) Viral antigens
GB201707093D0 (en) Viral antigens
GB201716047D0 (en) Virus
GB201700259D0 (en) Virus
GB201600380D0 (en) Modified virus
GB201600382D0 (en) Engineered virus